Cite
Choi SI, Jeon AR, Kim MK, et al. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Front Oncol. 2019;9:875doi: 10.3389/fonc.2019.00875.
Choi, S. I., Jeon, A. R., Kim, M. K., Lee, Y. S., Im, J. E., Koh, J. W., Han, S. S., Kong, S. Y., Yoon, K. A., Koh, Y. H., Lee, J. H., Lee, W. J., Park, S. J., Hong, E. K., Woo, S. M., & Kim, Y. H. (2019). Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Frontiers in oncology, 9875. https://doi.org/10.3389/fonc.2019.00875
Choi, Sun Il, et al. "Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples." Frontiers in oncology vol. 9 (2019): 875. doi: https://doi.org/10.3389/fonc.2019.00875
Choi SI, Jeon AR, Kim MK, Lee YS, Im JE, Koh JW, Han SS, Kong SY, Yoon KA, Koh YH, Lee JH, Lee WJ, Park SJ, Hong EK, Woo SM, Kim YH. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Front Oncol. 2019 Sep 13;9:875. doi: 10.3389/fonc.2019.00875. eCollection 2019. PMID: 31572675; PMCID: PMC6753223.
Copy
Download .nbib